Revenue Growth Momentum
DGX grew total revenue to $2,895M in Q1 FY2026, up 9.2% from $2,652M in the prior-year period, reflecting continued demand for diagnostic and laboratory services.
来源: 10-Q Income Statement
该报告暂无中文版，以下为英文版分析。
按公开的固定规则计算，不是模型的主观判断——但其中一项输入（高等级风险的条数）取自下方的 AI 分析。
非投资建议，也不是目标价——评的是本季基本面，不是股价。 完整方法论 →
AI核心结论
DGX delivered solid Q1 FY2026 results with revenue of $2.90B (+9.2% YoY) and net income of $252M (+14.5% YoY), driven by operating leverage that expanded operating margin to 13.8%.
营收
28.95亿美元
同比 +9.16%
每股收益（稀释）
2.24美元
同比 +15.46%
营业利润
3.99亿美元
同比 +15.32%
SEC XBRL 原值
Quest Diagnostics (DGX) Q1 FY2026 营收 28.95亿美元，同比增长 9.2%。 营业利润率 13.8%，较去年同期的 13.0% 扩大 0.8 个百分点。 经营活动现金流 2.78亿美元，同比下降 11.5%。 DGX 的财年 Q1 FY2026 对应日历 Q1 2026。
近 4 个季度：4 次超预期
| 季度 | 实际 EPS（美元） | 市场预期（美元） | 结果 |
|---|---|---|---|
| 2026年6月 | 3.12 | 2.85 | 超预期 +9.3% |
| 2026年3月本次财报 | 2.50 | 2.37 | 超预期 +5.5% |
| 2025年12月 | 2.42 | 2.38 | 超预期 +1.5% |
| 2025年9月 | 2.60 | 2.53 | 超预期 +2.8% |
2026年3月 调整后（非 GAAP） EPS 2.50美元，分析师一致预期 2.37美元，超预期 +5.5%。 分析师一致预期按市场通行的调整后（非 GAAP）口径。本季 GAAP 稀释每股收益为 2.24美元。
由 AI 基于本次 SEC 报告整理
DGX grew total revenue to $2,895M in Q1 FY2026, up 9.2% from $2,652M in the prior-year period, reflecting continued demand for diagnostic and laboratory services.
来源: 10-Q Income Statement
Operating income rose 15.3% YoY to $399M, outpacing revenue growth and expanding operating margin by approximately 73 basis points to 13.8%, suggesting cost discipline relative to top-line growth.
来源: 10-Q Income Statement
Net income increased 14.5% YoY to $252M, with diluted EPS rising 15.5% to $2.24 from $1.94, reflecting both earnings growth and the benefit of share count management.
来源: 10-Q Income Statement
Cash and equivalents more than doubled YoY to $393M (+109%), and current assets grew 23.7% to $2,566M, though current liabilities surged 51.1% to $2,177M, keeping the current ratio at a modest 1.18x.
来源: 10-Q Balance Sheet
Operating cash flow declined 11.5% YoY to $278M from $314M, while capital expenditures (implied by investing cash flow of -$152M) resulted in free cash flow of approximately $126M, a notable softening versus the prior year.
来源: 10-Q Cash Flow Statement
由 AI 基于本次 SEC 报告整理 · 高 0 中 3 低 2
Current liabilities jumped 51.1% YoY to $2,177M, significantly outpacing the 23.7% growth in current assets. This compressed the current ratio to 1.18x, leaving limited liquidity headroom and raising the risk of near-term cash flow pressure if operating conditions deteriorate.
来源: 10-Q Balance Sheet
Despite strong net income growth of 14.5%, operating cash flow fell 11.5% YoY to $278M, indicating a potential build-up in working capital or non-cash adjustments. Sustained divergence between earnings and cash generation could constrain capital allocation flexibility.
来源: 10-Q Cash Flow Statement
Cost of revenue grew 9.2% YoY to $1,953M, exactly matching the revenue growth rate, meaning gross profit improvement was driven entirely by volume rather than pricing power or cost efficiency. Any cost inflation could quickly erode gross margins.
来源: 10-Q Income Statement
ROA of 1.51% and ROE of 3.42% on a quarterly basis are relatively modest, suggesting the company's large asset base ($16.7B total assets) and equity base ($7.4B) are not generating outsized returns. This may reflect the capital-intensive nature of the diagnostic services business.
来源: 10-Q Balance Sheet & Income Statement
SG&A expenses rose 5.9% YoY to $504M, representing a meaningful absolute cost base relative to operating income of $399M. While growth was slower than revenue, any acceleration in SG&A spending could weigh on operating margin expansion.
来源: 10-Q Income Statement
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
营收 亿美元 | 28.95 亿美元 | 26.52 亿美元 | +9.16% |
营业成本 亿美元 | 19.53 亿美元 | 17.89 亿美元 | +9.17% |
营业利润 亿美元 | 3.99 亿美元 | 3.46 亿美元 | +15.32% |
净利润 亿美元 | 2.52 亿美元 | 2.20 亿美元 | +14.55% |
每股收益（基本） 美元 | 2.27 美元 | 1.97 美元 | +15.23% |
每股收益（稀释） 美元 | 2.24 美元 | 1.94 美元 | +15.46% |
销售及管理费用 亿美元 | 5.04 亿美元 | 4.76 亿美元 | +5.88% |
答案基于本次 SEC 报告与本页数据